表紙:バイオシミラーの世界市場 (~2026年):製品 (モノクローナル抗体 (インフリキシマブ・リツキシマブ・トラスツズマブ)・インスリン・インターフェロン・エタネルセプト・グルカゴン・カルシトニン)・適応症 (癌・慢性疾患・血液疾患・自己免疫疾患)・地域別
市場調査レポート
商品コード
1031216

バイオシミラーの世界市場 (~2026年):製品 (モノクローナル抗体 (インフリキシマブ・リツキシマブ・トラスツズマブ)・インスリン・インターフェロン・エタネルセプト・グルカゴン・カルシトニン)・適応症 (癌・慢性疾患・血液疾患・自己免疫疾患)・地域別

Biosimilars Market by Product (Monoclonal antibodies (infliximab, rituximab, trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region/Global Forecast -2026

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 224 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
バイオシミラーの世界市場 (~2026年):製品 (モノクローナル抗体 (インフリキシマブ・リツキシマブ・トラスツズマブ)・インスリン・インターフェロン・エタネルセプト・グルカゴン・カルシトニン)・適応症 (癌・慢性疾患・血液疾患・自己免疫疾患)・地域別
出版日: 2021年10月01日
発行: MarketsandMarkets
ページ情報: 英文 224 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のバイオシミラーの市場規模は予測期間中23.5%のCAGRで推移し、2021年の156億米ドルから、2026年には447億米ドルの規模に成長すると予測されています。

慢性疾患の発症率の上昇、費用対効果の高さ、各国の規制当局の承認やその他の規制がバイオシミラーの採用を後押ししていることなどの要因が同市場の成長を推進しています。一方で、バイオシミラーの開発・製造が複雑であることや、先発製剤メーカーからの抵抗が、予測期間中の市場成長を抑制すると予測されています。

製品別で見ると、モノクローナル抗体の部門が予測期間中最大の成長を示すと予測されています。また、2020年においては、27.5%で最大のシェアを示しています。これは、バイオシミラーのモノクローナル抗体が先発薬に比べて低価格であることや、癌、自己免疫疾患、骨粗鬆症などの治療に広く使用されていることなどに起因しています。また、適応症別では、癌の部門が最大のシェアを示しています。バイオシミラーの低価格性や癌の発症率の高さが同部門の成長を牽引しています。

当レポートでは、世界のバイオシミラーの市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、技術動向、市場規模の推移・予測、製品・適応症・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
    • 動向
  • COVID-19:影響分析
  • 技術分析
  • バリューチェーン分析
  • エコシステム
  • サプライチェーン分析
  • ポーターのファイブフォース分析
  • 規制状況

第6章 バイオシミラー市場:製品別

  • モノクローナル抗体
    • インフリキシマブ
    • トラスツズマブ
    • リツキシマブ
    • アダリムマブ
    • その他
  • インスリン
  • 顆粒球コロニー刺激因子
  • エリスロポエチン
  • 組換えヒト成長ホルモン
  • エタネルセプト
  • 卵胞刺激ホルモン
  • テリパラチド
  • インターフェロン
  • エノキサパリンナトリウム
  • グルカゴン
  • カルシトニン

第7章 バイオシミラー市場:適応症別

  • 腫瘍
  • 炎症性および自己免疫疾患
  • 慢性疾患
  • 血液疾患
  • 成長ホルモン欠乏症
  • 感染症
  • その他

第8章 バイオシミラー市場:地域別

  • 欧州
  • アジア太平洋
  • 北米
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合情勢

  • 成功アプローチ
  • 主要企業の収益シェア分析
  • 市場シェア分析
  • 企業評価クアドラント
  • 企業評価クアドラント:新興企業/中小企業
  • 競合ベンチマーキング
  • 新興企業・主要企業の成長戦略

第10章 企業プロファイル

  • 主要企業
    • NOVARTIS AG
    • PFIZER INC.
    • DR. REDDY'S LABORATORIES LTD.
    • AMGEN INC.
    • ELI LILLY AND COMPANY
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • FRESENIUS SE & CO. KGAA
    • STADA ARZNEIMITTEL AG
    • BOEHRINGER INGELHEIM
    • GEDEON RICHTER PLC
    • CELLTRION
    • SAMSUNG BIOLOGICS
    • COHERUS BIOSCIENCES
    • BIOCON LIMITED
    • VIATRIS
  • その他の企業
    • AMEGA BIOTECH
    • APOTEX INC.
    • BIOCAD
    • MABXIENCE
    • PROBIOMED S.A. DE C.V.
    • FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
    • INTAS PHARMACEUTICALS LTD.
    • THERAMEX
    • RELIANCE LIFE SCIENCES
    • KASHIV BIOSCIENCES

第11章 付録

目次
Product Code: PH 7582

The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026. Market growth is largely driven by the rising incidence of chronic diseases and increasing demand of biosimilars for their cost-effectiveness. Regulatory approvals and other regulations favouring biosimilars adoption in different countries is also a major driving factor in the biosimilars market. However, the complexities in the development and manufacturing of biosimilars and resistance from reference biologic manufacturers is expected to restrain the growth of this market during the forecast period.

"The monoclonal antibodies productsegment accounted for the highest growth rate in the biosimilarsmarket, byproduct, during the forecast period"

In 2020, the monoclonal antibodies product segment accounted for the largest share (27.5%) of the biosimilars market, mainly due to the low prices of biosimilar monoclonal antibodies compared to the reference drugs and their wide use in the treatment of cancer, autoimmune disorders, and osteoporosis. They are also used in indications such as rheumatoid arthritis, multiple sclerosis, and macular degeneration. The growth of the fastest-growing segment was attributed to the rising incidence of cancer cases and chronic diseases and growth in the geriatric population.

"Oncologysegment accounted for the largest share of the indication segment"

Based on the indication, the biosimilars market is segmented into oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, and other indications (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases). Oncology is the largest segment in this market owing to the availability of biosimilars at a lower price than innovative biologics and a large number of cancer patients. The availability of biosimilars in the field of oncology has lowered prices and made cancer treatment more affordable and accessible. Also, due to the high incidence and prevalence of cancer, healthcare systems across the globe are focusing on reducing the burden of cancer by adopting cost effective treatment options. In this scenario, biosimilar drugs might witness widespread adoption in major markets such as the US, Europe, and the Asia Pacific. Considering these factors and the upending competition from biosimilars, many major biologic pharmaceutical companies are making significant investments in the development and approval of biosimilar drugs.

"Asia Pacific: The fastest-growing regionin thebiosimilarsmarket"

Thebiosimilarsmarket is segmented into Europe, Asia Pacific, North America, latin America and Middle East and Africa. The APAC market, on the other hand, is expected to be the fastest-growing regional segment during the forecast period due to the presence of many emerging players, less-stringent regulations, and increasing cooperation among leading and regional players for development, manufacture and commercialization of biosimilars.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80%and Demand Side 20%
  • By Designation: Managers - 55%, CXOs - 20%, and Executives - 25%
  • By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:

  • Novartis AG (Switzerland)
  • Pfizer, Inc. (US)
  • Dr. Reddy's Laboratories Ltd (India)
  • Amgen, Inc. (US)
  • Eli Lilly and Company (US)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Fresenius SE & Co. KGaA (Germany)
  • STADA Arzneimittel AG (Germany)
  • Boehringer Ingelheim (Germany)
  • Gedeon Richter PLC (Hungary)
  • Celltrion (South Korea)
  • Samsung Biologics (South Korea)
  • CoherusBioSciences (US)
  • Biocon Limited (India)
  • Viatris, Inc. (US)
  • Amega Biotech (Argentina)
  • Apotex, Inc. (Canada)
  • Biocad (Russia)
  • mAbxience (Spain)
  • Probiomed S.A. De C.V. (Mexico)
  • Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan)
  • Intas Pharmaceuticals Ltd. (India)
  • Theramex (UK)
  • Reliance Life Sciences (India)
  • Kashiv Biosciences (US)

Research Coverage:

This report provides a detailed picture of thebiosimilars market. It aims at estimating the size and future growth potential of the market across different segments such as theproduct,indication and region. The report also includes an in-depth competitive analysis ofthe key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biosimilars marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers,restraints,trends,challengesand opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    • TABLE 1 BIOSIMILARS MARKET: INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS
  • 1.6 LIMITATIONS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
  • 2.2 SECONDARY DATA
    • FIGURE 2 SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • FIGURE 3 KEY DATA FROM PRIMARY SOURCES
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 5 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET ESTIMATION METHODOLOGY
    • 2.5.1 BOTTOM-UP APPROACH
    • 2.5.2 TOP-DOWN APPROACH
    • FIGURE 6 TOP-DOWN APPROACH
    • FIGURE 7 BIOSIMILARS MARKET: FINAL MARKET SIZE (USD BILLION)
  • 2.6 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
  • 2.7 INSIGHTS FROM PRIMARIES
    • FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.8 RESEARCH ASSUMPTIONS
  • 2.9 LIMITATIONS
  • 2.10 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

    • FIGURE 9 BIOSIMILARS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    • FIGURE 10 BIOSIMILARS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 11 BIOSIMILARS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 BIOSIMILARS MARKET OVERVIEW
    • FIGURE 12 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT AND COUNTRY (2020)
    • FIGURE 13 INSULIN HELD THE LARGEST SHARE OF THE NORTH AMERICAN BIOSIMILARS MARKET IN 2020
  • 4.3 GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET
    • FIGURE 14 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing demand for biosimilar drugs due to their cost-effectiveness
      • 5.2.1.2 Rising geriatric population and the increasing incidence of chronic diseases
    • FIGURE 16 GERIATRIC POPULATION, BY REGION, 2020 VS. 2030 VS. 2050 (MILLION)
    • FIGURE 17 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
      • 5.2.1.3 Abbreviated regulatory approval process and concept of interchangeability
    • FIGURE 18 COMPARISON OF REFERENCE PRODUCTS, BIOSIMILARS, AND INTERCHANGEABLE PRODUCTS
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Complexities in manufacturing
      • 5.2.2.2 Resistance from biologics manufacturers
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging markets
      • 5.2.3.2 Patent expiry of blockbuster biologics and research on new indications
    • TABLE 2 LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Excess competition
    • 5.2.5 TRENDS
      • 5.2.5.1 Collaborations for biosimilar research and clinical trials
    • TABLE 3 MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2017-2020)
  • 5.3 COVID-19 IMPACT ANALYSIS
  • 5.4 TECHNOLOGY ANALYSIS
    • TABLE 4 COMPARISON OF ORIGINAL BIOLOGICS WITH BIOSIMILARS
    • TABLE 5 GENERIC DRUGS VS. BIOSIMILARS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 19 VALUE CHAIN ANALYSIS FOR BIOSIMILARS
  • 5.6 ECOSYSTEM MARKET MAP
    • FIGURE 20 ECOSYSTEM MARKET MAP FOR BIOSIMILARS
  • 5.7 SUPPLY CHAIN ANALYSIS
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 PORTER'S FIVE FORCES: IMPACT ANALYSIS ON THE BIOSIMILARS MARKET
    • 5.8.1 THREAT FROM NEW ENTRANTS
    • 5.8.2 THREAT FROM SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITION RIVALRY
  • 5.9 REGULATORY LANDSCAPE
    • TABLE 7 REGULATORY LANDSCAPE FOR THE BIOSIMILARS MARKET

6 BIOSIMILARS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • FIGURE 21 BIOSIMILARS APPROVED IN THE US, EUROPE, AND CHINA, BY TYPE
    • TABLE 8 BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
  • 6.2 MONOCLONAL ANTIBODIES
    • TABLE 9 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 10 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.1 INFLIXIMAB
      • 6.2.1.1 Infliximab accounted for the largest share of the monoclonal antibodies market
    • TABLE 11 BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.2 TRASTUZUMAB
      • 6.2.2.1 Rising incidence of cancer to drive market growth
    • TABLE 12 BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.3 RITUXIMAB
      • 6.2.3.1 Rising incidence of autoimmune diseases and cancer are key drivers for market growth
    • TABLE 13 BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.4 ADALIMUMAB
      • 6.2.4.1 Adalimumab to register the highest CAGR in the monoclonal antibodies market
    • TABLE 14 BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.5 OTHER MONOCLONAL ANTIBODIES
    • TABLE 15 BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2019-2026 (USD MILLION)
  • 6.3 INSULIN
    • 6.3.1 INCREASING INCIDENCE OF DIABETES TO SUPPORT MARKET GROWTH
    • TABLE 16 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2019-2026 (USD MILLION)
  • 6.4 GRANULOCYTE COLONY-STIMULATING FACTOR
    • 6.4.1 G-CSF IS USED TO TREAT CANCER PATIENTS WITH NEUTROPENIA OCCURRING AFTER CHEMOTHERAPY
    • TABLE 17 LIST OF APPROVED BIOSIMILARS FOR G-CSF
    • TABLE 18 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2019-2026 (USD MILLION)
  • 6.5 ERYTHROPOIETIN
    • 6.5.1 RISING INCIDENCE OF BLOOD DISORDERS WILL DRIVE MARKET GROWTH
    • TABLE 19 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
    • TABLE 20 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2019-2026 (USD MILLION)
  • 6.6 RECOMBINANT HUMAN GROWTH HORMONE
    • 6.6.1 MARKET GROWTH IS DRIVEN PRIMARILY BY THE INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS
    • TABLE 21 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2019-2026 (USD MILLION)
  • 6.7 ETANERCEPT
    • 6.7.1 APAC TO WITNESS THE HIGHEST GROWTH IN THE ETANERCEPT MARKET DURING THE FORECAST PERIOD
    • TABLE 22 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2019-2026 (USD MILLION)
  • 6.8 FOLLITROPIN
    • 6.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT TO DRIVE MARKET GROWTH
    • TABLE 23 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2019-2026 (USD MILLION)
  • 6.9 TERIPARATIDE
    • 6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS IS THE MAJOR FACTOR DRIVING MARKET GROWTH
    • TABLE 24 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2019-2026 (USD MILLION)
  • 6.10 INTERFERONS
    • 6.10.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
    • TABLE 25 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2019-2026 (USD MILLION)
  • 6.11 ENOXAPARIN SODIUM
    • 6.11.1 WIDE RANGE OF APPLICATIONS HAVE SUPPORTED THE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS
    • TABLE 26 BIOSIMILARS MARKET FOR ENOXAPARIN SODIUM, BY REGION, 2019-2026 (USD MILLION)
  • 6.12 GLUCAGON
    • 6.12.1 SANDOZ IS A MAJOR PLAYER IN THE GLUCAGON BIOSIMILARS MARKET
    • TABLE 27 BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2019-2026 (USD MILLION)
  • 6.13 CALCITONIN
    • 6.13.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO DRIVE MARKET GROWTH
    • TABLE 28 BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2019-2026 (USD MILLION)

7 BIOSIMILARS MARKET, BY INDICATION

  • 7.1 INTRODUCTION
    • TABLE 29 BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
  • 7.2 ONCOLOGY
    • 7.2.1 RISING BURDEN OF CANCER TO DRIVE THE DEMAND FOR BIOSIMILARS
    • FIGURE 22 CANCER CASES, BY TYPE, 2020 (MILLION)
    • FIGURE 23 DEATHS DUE TO CANCER, BY TYPE, 2020 (MILLION)
    • TABLE 30 BIOSIMILARS APPROVED BY THE US FDA FOR ONCOLOGICAL INDICATIONS, 2018-2020
    • FIGURE 24 ARTICLES PUBLISHED ON BIOSIMILARS FOR ONCOLOGY, 2012-2020
    • TABLE 31 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2019-2026 (USD MILLION)
  • 7.3 INFLAMMATORY & AUTOIMMUNE DISEASES
    • 7.3.1 CHANGES IN LIFESTYLE AND ENVIRONMENTAL CONDITIONS HAVE INCREASED THE INCIDENCE OF INFLAMMATORY & AUTOIMMUNE DISEASES
    • TABLE 32 BIOSIMILARS MARKET FOR INFLAMMATORY AND AUTOIMMUNE DISEASES, BY REGION, 2019-2026 (USD MILLION)
  • 7.4 CHRONIC DISEASES
    • 7.4.1 HIGH BURDEN OF CVD & DIABETES WORLDWIDE TO DRIVE MARKET GROWTH
    • TABLE 33 BIOSIMILARS APPROVED BY THE US FDA FOR CHRONIC DISEASES, 2018-2020
    • TABLE 34 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2019-2026 (USD MILLION)
  • 7.5 BLOOD DISORDERS
    • 7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS HAS INCREASED THE DEMAND FOR BIOSIMILARS FOR THIS INDICATION SEGMENT
    • TABLE 35 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2019-2026 (USD MILLION)
  • 7.6 GROWTH HORMONE DEFICIENCY
    • 7.6.1 GROWING USE OF BIOSIMILARS FOR THE TREATMENT OF THIS MEDICAL CONDITION TO SUPPORT MARKET GROWTH
    • TABLE 36 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2019-2026 (USD MILLION)
  • 7.7 INFECTIOUS DISEASES
    • 7.7.1 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES IS EXPECTED TO BE THE HIGHEST IN THE ASIA PACIFIC
    • TABLE 37 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019-2026 (USD MILLION)
  • 7.8 OTHER INDICATIONS
    • TABLE 38 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2019-2026 (USD MILLION)

8 BIOSIMILARS MARKET, BY REGION

  • 8.1 INTRODUCTION
    • FIGURE 25 BIOSIMILARS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • TABLE 39 BIOSIMILARS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 8.2 EUROPE
    • TABLE 40 LIST OF BIOSIMILARS APPROVED IN EUROPE
    • FIGURE 26 EUROPE: BIOSIMILARS MARKET SNAPSHOT
    • TABLE 41 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 42 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 43 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 44 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.2.1 UK
      • 8.2.1.1 The UK holds the largest share of the biosimilars market in Europe
    • TABLE 45 LIST OF BIOSIMILARS IN THE UK
    • TABLE 46 UK: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 47 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 48 UK: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.2.2 FRANCE
      • 8.2.2.1 Rising geriatric population will drive market growth
    • TABLE 49 FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 50 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 51 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.2.3 GERMANY
      • 8.2.3.1 Presence of a favorable pricing system has supported biosimilar adoption in Germany
    • TABLE 52 GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 53 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 54 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.2.4 ITALY
      • 8.2.4.1 Rising geriatric population in Italy will support the adoption of biosimilars in the country
    • TABLE 55 ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 56 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 57 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.2.5 SPAIN
      • 8.2.5.1 Patient incentives to promote biosimilar use is a key growth driver for the biosimilars market in Spain
    • TABLE 58 SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 59 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 60 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.2.6 REST OF EUROPE
    • TABLE 61 ROE: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 62 ROE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 63 ROE: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
  • 8.3 ASIA PACIFIC
    • FIGURE 27 ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
    • TABLE 64 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 66 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.3.1 INDIA
      • 8.3.1.1 India held the largest share of the APAC biosimilars market
    • TABLE 68 BIOSIMILARS APPROVED AND MARKETED IN INDIA
    • TABLE 69 INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 70 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 71 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.3.2 CHINA
      • 8.3.2.1 China is the fastest-growing market for biosimilars in the APAC
    • TABLE 72 BIOSIMILARS APPROVED IN CHINA
    • TABLE 73 CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 74 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 75 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.3.3 SOUTH KOREA
      • 8.3.3.1 Favorable government initiatives to drive the market in South Korea
    • TABLE 76 LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA
    • TABLE 77 SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 78 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 79 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.3.4 JAPAN
      • 8.3.4.1 Large geriatric population in the country to drive market growth
    • TABLE 80 LIST OF BIOSIMILARS APPROVED IN JAPAN
    • TABLE 81 JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 82 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 83 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.3.5 AUSTRALIA
      • 8.3.5.1 Incremental changes in biosimilar regulations and increasing incidence of chronic diseases to drive market growth
    • TABLE 84 LIST OF BIOSIMILARS APPROVED IN AUSTRALIA
    • TABLE 85 AUSTRALIA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 86 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 87 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.3.6 REST OF ASIA PACIFIC
    • TABLE 88 LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
    • TABLE 89 LIST OF BIOSIMILARS APPROVED IN MALAYSIA
    • TABLE 90 LIST OF BIOSIMILARS APPROVED IN SINGAPORE
    • TABLE 91 ROAPAC: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 92 ROAPAC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 93 ROAPAC: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
  • 8.4 NORTH AMERICA
    • TABLE 94 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 95 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 96 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 97 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.4.1 US
      • 8.4.1.1 The US dominates the North American biosimilars market
    • TABLE 98 LIST OF BIOSIMILARS APPROVED IN THE US
    • TABLE 99 US: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 100 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 101 US: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • 8.4.2 CANADA
      • 8.4.2.1 Favorable government initiatives to support market growth
    • TABLE 102 LIST OF BIOSIMILARS APPROVED IN CANADA
    • TABLE 103 CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 104 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 105 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
  • 8.5 LATIN AMERICA
    • 8.5.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
    • TABLE 106 LIST OF BIOSIMILARS APPROVED IN LATIN AMERICA
    • TABLE 107 LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 108 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 109 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
  • 8.6 MIDDLE EAST AND AFRICA
    • 8.6.1 FAVORABLE REGULATORY REFORMS AND INFRASTRUCTURAL DEVELOPMENT TO FAVOR MARKET GROWTH
    • TABLE 110 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 111 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 112 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2019-2026 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 INTRODUCTION
  • 9.2 RIGHT-TO-WIN APPROACH
    • FIGURE 28 KEY DEVELOPMENTS OF MAJOR PLAYERS, JANUARY 2018-AUGUST 2021
  • 9.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
    • FIGURE 29 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST THREE YEARS
  • 9.4 MARKET SHARE ANALYSIS
    • FIGURE 30 GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
  • 9.5 COMPANY EVALUATION QUADRANT
    • 9.5.1 STARS
    • 9.5.2 EMERGING LEADERS
    • 9.5.3 PERVASIVE PLAYERS
    • 9.5.4 PARTICIPANTS
    • FIGURE 31 BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT, 2020
  • 9.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 9.6.1 PROGRESSIVE COMPANIES
    • 9.6.2 STARTING BLOCKS
    • 9.6.3 RESPONSIVE COMPANIES
    • 9.6.4 DYNAMIC COMPANIES
    • FIGURE 32 BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
  • 9.7 COMPETITIVE BENCHMARKING
    • 9.7.1 COMPANY PRODUCT FOOTPRINT
    • 9.7.2 COMPANY INDICATION FOOTPRINT
    • 9.7.3 COMPANY REGIONAL FOOTPRINT
  • 9.8 GROWTH STRATEGIES ADOPTED BY EMERGING AND KEY PLAYERS
    • 9.8.1 PRODUCT LAUNCHES & APPROVALS
    • 9.8.2 DEALS
    • 9.8.3 OTHER DEVELOPMENTS

10 COMPANY PROFILES

  • 10.1 MAJOR PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 10.1.1 NOVARTIS AG
    • TABLE 113 NOVARTIS AG: BUSINESS OVERVIEW
    • FIGURE 33 SANDOZ: COMPANY SNAPSHOT (2020)
    • 10.1.2 PFIZER INC.
    • TABLE 114 PFIZER INC: BUSINESS OVERVIEW
    • FIGURE 34 PFIZER INC.: COMPANY SNAPSHOT (2020)
    • 10.1.3 DR. REDDY'S LABORATORIES LTD.
    • TABLE 115 DR. REDDY'S LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 35 DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT (2020)
    • 10.1.4 AMGEN INC.
    • TABLE 116 AMGEN INC.: BUSINESS OVERVIEW
    • FIGURE 36 AMGEN INC.: COMPANY SNAPSHOT (2020)
    • 10.1.5 ELI LILLY AND COMPANY
    • TABLE 117 ELI LILLY AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 37 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020)
    • 10.1.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 118 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
    • FIGURE 38 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2020)
    • 10.1.7 FRESENIUS SE & CO. KGAA
    • TABLE 119 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
    • FIGURE 39 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2020)
    • 10.1.8 STADA ARZNEIMITTEL AG
    • TABLE 120 STADA ARZNEIMITTEL: BUSINESS OVERVIEW
    • FIGURE 40 STADA ARZNEIMITTEL: COMPANY SNAPSHOT (2020)
    • 10.1.9 BOEHRINGER INGELHEIM
    • TABLE 121 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW
    • FIGURE 41 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2020)
    • 10.1.10 GEDEON RICHTER PLC
    • TABLE 122 GEDEON RICHTER PLC: BUSINESS OVERVIEW
    • FIGURE 42 GEDEON RICHTER PLC: COMPANY SNAPSHOT (2020)
    • 10.1.11 CELLTRION
    • TABLE 123 CELLTRION: BUSINESS OVERVIEW
    • FIGURE 43 CELLTRION: COMPANY SNAPSHOT (2020)
    • 10.1.12 SAMSUNG BIOLOGICS
    • TABLE 124 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
    • FIGURE 44 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2020)
    • 10.1.13 COHERUS BIOSCIENCES
    • TABLE 125 COHERUS BIOSCIENCES: BUSINESS OVERVIEW
    • FIGURE 45 COHERUS BIOSCIENCES: COMPANY SNAPSHOT (2020)
    • 10.1.14 BIOCON LIMITED
    • TABLE 126 BIOCON LIMITED: BUSINESS OVERVIEW
    • FIGURE 46 BIOCON LIMITED: COMPANY SNAPSHOT (2020)
    • 10.1.15 VIATRIS
    • TABLE 127 VIATRIS: BUSINESS OVERVIEW
  • 10.2 OTHER PLAYERS
    • 10.2.1 AMEGA BIOTECH
    • TABLE 128 AMEGA BIOTECH: BUSINESS OVERVIEW
    • 10.2.2 APOTEX INC.
    • TABLE 129 APOTEX INC.: BUSINESS OVERVIEW
    • 10.2.3 BIOCAD
    • TABLE 130 BIOCAD: BUSINESS OVERVIEW
    • 10.2.4 MABXIENCE
    • TABLE 131 MABXIENCE: BUSINESS OVERVIEW
    • 10.2.5 PROBIOMED S.A. DE C.V.
    • TABLE 132 PROBIOMED: BUSINESS OVERVIEW
    • 10.2.6 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
    • TABLE 133 FUJIFILM KYOWA KIRIN BIOLOGICS: BUSINESS OVERVIEW
    • 10.2.7 INTAS PHARMACEUTICALS LTD.
    • TABLE 134 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
    • 10.2.8 THERAMEX
    • TABLE 135 THERAMEX: BUSINESS OVERVIEW
    • 10.2.9 RELIANCE LIFE SCIENCES
    • TABLE 136 RELIANCE LIFE SCIENCES: BUSINESS OVERVIEW
    • 10.2.10 KASHIV BIOSCIENCES
    • TABLE 137 KASHIV BIOSCIENCES: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS